Biologic Therapy for Refractory Pityriasis Rubra Pilaris
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/1232693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 15.07.2026. Verfasst von Chenmei Liu und 3 weiteren Autor:innen. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pityriasis rubra pilaris (PRP) is a rare, heterogeneous inflammatory dermatosis with no standardized treatment guidelines. Conventional therapies often fail to achieve sustained remission in refractory cases, particularly in the erythrodermic and pediatric subtypes. Biologics targeting tumor necrosis factor (TNF)‐α, interleukin (IL)‐17, and IL‐23 have been increasingly reported as off‐label treatment options. However, evidence remains fragmented, and consensus on treatment selection and sequencing for biologic nonresponders is lacking.
Objective
To evaluate the real‐world clinical outcomes associated with biologic therapy in treatment‐resistant PRP via a retrospective case series and a scoping review of published evidence.
Methods
Four patients with difficult‐to‐treat PRP (including one pediatric case) treated with biologic agents between 2022 and 2025 were included in the analysis. Clinical response was assessed by physician‐documented changes in erythema, scaling, and body surface area (BSA) involvement. A scoping review of PubMed, Embase, and the Cochrane Library (January 2015 to December 2025) was conducted in accordance with the PRISMA Extension for Scoping Reviews (PRISMA‐ScR) to identify English‐language clinical studies reporting on biologic therapy for PRP.
Results
In this small retrospective series, all four patients showed clinical improvement during biologic therapy, with no serious adverse events observed. Three patients with suboptimal or incomplete responses to IL‐17A inhibitors underwent cross‐class switching to IL‐23 or IL‐12/23 inhibitors, followed by improved disease control. One pediatric patient responded well to IL‐17A inhibitor monotherapy. The scoping review included 76 clinical publications in the core evidence synthesis and 14 background or mechanistic publications retained for contextual discussion. Therapeutic responses to TNF‐α inhibitors, IL‐17 pathway inhibitors, IL‐12/23 inhibitors, and IL‐23 inhibitors were reported across PRP subtypes, although response durability, relapse, and loss of response varied across published reports.
Conclusion
Biologic therapy was associated with meaningful clinical improvement in this small retrospective series of refractory PRP, and cross‐class biologic switching appeared feasible in selected patients with an inadequate initial response. These findings should be interpreted as preliminary and hypothesis‐generating. Larger prospective studies with standardized outcome measures are needed.
Zitieren
APA
Liu, C., Gahimbare, F., Zhang, J., & Yang, B. (2026). Biologic Therapy for Refractory Pityriasis Rubra Pilaris. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/1232693
Vancouver
Liu C, Gahimbare F, Zhang J, Yang B. Biologic Therapy for Refractory Pityriasis Rubra Pilaris. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/1232693
BibTeX
@article{Liu2026,
author = {Liu, Chenmei and Gahimbare, Freddy and Zhang, Junfen and Yang, Bin},
title = {Biologic Therapy for Refractory Pityriasis Rubra Pilaris},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/1232693}
}
EUVIMED